TAK-981, an Inhibitor For SUMOylation Enzymatic Cascade with Antineoplastic Activities
Recently, National Cancer Institute has reported a novel inhibitor TAK-981 for SUMOylation enzymatic cascade. This inhibitor showed potential immune-activating and antineoplastic activities. Firstly, TAK-981 targets and covalently binds to the…